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ABSTRACT
Objective: To assess the serum level of Semaphorin 3A in ankylosing
spondylitis (AS) patients and to assess its correlation with disease activity.
Subjects and Methods: The study was carried on 40 subjects, 20 AS patients
(12 males and 8 females) fulfilled the 1984 Modified New York criteria for
diagnosis of ankylosing spondylitis, and 20 healthy subjects, taken as control
group (12 females and 8 males). A consent was taken from all subjects to share
in the study. Disease Activity Score (ASDAS) was calculated for AS patients
and functional assessment was done using the Bath Ankylosing Spondylitis
Functional Index (BASFI).
Results: Serum levels of Semaphorin 3A were significantly higher(P<0.05) in
AS patients more than controls as it ranged between 0.22-31.48 years with a
median of 2.93 in AS patients and (0.04-3.91) with the median of 1.83in
controls. Also, there was a significant difference(P<0.05) of Serum
Semaphorin 3A level in ankylosing spondylitis patients regarding ASDASCRP score being higher in active AS (ASDAS-CRP ≥1.3) and ranged between
(2.17-31.48) vs (0.22- 2.23) in the active vs the inactive AS patients
respectively. Serum Semaphorin 3A level (ng/ml) in ankylosing spondylitis
patients were significantly correlated with ASDAS- CRP (r=0.82), ASDASESR (r=0.76) as p<0.05.
Conclusion: Serum levels of Semaphorin 3A were increased in patients with
ankylosing sponndylitis and correlated with disease activity. So, Semaphorin
3A can be used as a biomarker for AS disease activity.
Keyword: Ankylosing spondylitis- Semaphorin 3A- biomarker.

INTRODUCTION
nkylosing spondylitis (AS) is an autoimmune disease which is characterized by
inflammatory back pain with inactivity
stiffness, enthesitis, sacroiliitis, peripheral
arthritis, and anterior uveitis. AS may have
significant mental and economical burdens in
the patients and the society as a whole (1). AS
burden results from back pain due to acute
inflammation and limitation of spinal mobility
due to new bone formation (2) .
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Regarding the acute inflammation
occurring in ankylosing spondylitis, both
interleukin (IL)-23/IL-17 axis and T helper-17
(Th17) cells are major players(3). When
stimulated by IL-23 cytokine, Th17 cells
produce proinflammatory cytokines including
tumor necrosis factor (TNF)-alpha, interferon
(IFN)-gamma, interleukin (IL-6), and IL-17.
IL-17 was showed to stimulate T cells,
macrophages, other cells to produce cytokines
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which promote inflammation including TNFalpha, IL-1 and IL-6(2).
Moreover, AS is characterized by
formation of new bone in the form of
enthesophytes originating from the entheses
where ligaments and tendons are inserted in
bones, syndesmophytes joining adjacent
intervertebral bodies and bony changes of the
sacroiliac joints leading to their ankylosis (4).
Semaphorins are formed of ‘Sema’ part
containing amino acids and c-terminal part.
They include eight subclasses. Classes 1 and
class 2 are present in the invertebrate while
Classes 3-7 are found in vertebrates. However,
class 8 is virus encoded (5 ). Class 1 and 4–7
semaphorins are membrane-bound but classes
2, 3 and 8 are secreted (6).
Semaphorins are secreted by many cells
including
neuronal
cells,
cells
of
cardiovascular, gastrointestinal, hepatic, renal
and reproductive systems (7), cancer and
immune cells (10). In addition, they are secreted
by all bone cells including osteoclasts,
osteoblasts, and osteocytes (5). They have
different functions as bone remodeling, bone
diseases pathology, immune regulation,
angiogenesis, cardiac development and cancer
growth(5).
Semaphorins bind to both neuropilins
and plexins receptors. The plexins function is
signal transduction while neurophilins are the
sites where Semaphorins bind. The neurophilins
include NP-1 and NP-2 subtypes (8).
It was found that Semaphorin 3A (Sema
3A) and its receptors, plexins, NP-1 and NP-2,
Sema 3A was expressed on multiple immune
cells including activated T-cells and
differentiating macrophages. So, it was
suggested that Sema 3A may play a vital role
in inflammatory diseases including ankylosing
spondylitis disease (9).
In addition, Sema 3A and its receptors
were found to be expressed by osteoblasts,
osteoclasts and osteoclast precursors. It was
suggested that Sema 3A could stimulate the
process of bone formation through induction of
osteoblast differentiation and inhibit the process
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of bone resorption through suppression of
osteoclast differentiation (10).
This study aimed to find out the
correlation of Sema 3A with disease activity in
ankylosing spondylitis patients. This study
selected class 3 Semaphorins as they were
shown to play a role in the pathogenesis of
autoimmune diseases as rheumatoid arthritis,
systemic sclerosis and systemic lupus
erythematosus, so, it may play a role in AS
pathogenesis (11)
Subjects and methods:
This study was performed in Rheumatology and
Rehabilitation
Department,
Faculty
of
Medicine, Zagazig University on 40 subjects
divided into two groups: Group I (AS group)
and group II (control group). Group I included
20 AS patients diagnosed according to 1984
Modified New York criteria for ankylosing
spondylitis (12) but group II included 20
apparently healthy control subjects, age and sex
matched with patients.
Written informed consent was obtained from all
participants and the study was approved by the
research ethical committee of Faculty of
Medicine, Zagazig University. The work has
been carried out in accordance with The Code
of Ethics of the World Medical Association
(Declaration of Helsinki) for studies involving
humans.
Exclusion criteria:
Patients with osteoporosis or bony fractures or
osteoarthritis or chronic kidney disease.
Patients who are on anticoagulants.
Patients with other autoimmune diseases as
rheumatoid arthritis, scleroderma, Systemic
lupus erythematosus, dermatomyositis, mixed
connective tissue disease, psoriatic arthritis
were excluded.
We subjected the AS patients to:
Full history taking.
Full clinical examination (general and
musculoskeletal system examination).
Calculation of disease activity scores:
Ankylosing Spondylitis Disease Activity Score
(ASDAS) (13).
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Functional assessment by the Bath Ankylosing
Spondylitis Functional Index (BASFI) (14).
Laboratory
investigations:
Erythrocyte
sedimentation rate (ESR) and C-reactive
protein (CRP).
C-reactive protein (CRP):
It
was
measured
by
immunoturbidimetric assay on Cobas 6000
analyzer.
Serum Semaphorin 3A level:
It was measured in both patients and
controls serum samples by enzyme-linked
immunosorbent assay (ELISA) using Human
Semaphorin 3A (Sema 3A) ELISA Kit
according to the instruction of the manufacturer
(SunRed, Shanghi). Venous blood samples
were taken from each subject under aseptic
condition, left for 20-30 minutes for
spontaneous clotting then centrifuged at 4000
rounds per minute for 10 minutes then serums
were collected and stored at -20° C until
Semaphorin determination. All the work was
carried out in the laboratory of the Clinical
Pathology Department.
Statistical Methods:
All data were statistically analyzed using SPSS
20.0 for windows (SPSS Inc., Chicago, IL,
USA 2011). Quantitative data were expressed
as the mean ± SD & minimum to maximum
range but qualitative data were expressed as
percentage.
To compare between two groups of normally
distributed variables, independent samples
Student's t-test was used. On the other hand, we
used Mann Whitney U test to compare between
two groups of non-normally distributed
variables.
P-values < 0.05 were considered statistically
significant and p-values ≥ 0.05 were considered
statistically non-significant.
Results:
All AS patients included in the study
were diagnosed according to 1984 Modified
New York criteria for ankylosing spondylitis
and had radiographic sacroiliitis grade ≥ 2
bilaterally or grade 3-4 unilaterally (12).
The mean age of AS patients was 32.8±
7.7 years, the mean of disease duration was
Abd Elhady A., et al
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8.7±8.5 years. They were 12 males and 8
females. There was non-significant difference
between ankylosing spondylitis patients and
controls regarding age and sex (P>0.05)
(Table1).
Table.2 demonstrates characteristics of
AS patients.14 patients had peripheral arthritis
in addition to axial arthritis (70%) while 6 AS
patients had isolated axial arthritis (20%), only
one patient had uveitis (5%), lateral flexion
ranged from (2-22) cm and the median was 8.5
cm, Schober test ranged between (11-16) cm
and the median was 12.75 cm, Chest Expansion
ranged between (2-6) cm and the median was 4
cm, ESR ranged from (4-100) mm/h and the
median was 30 mm/hr., CRP ranged between
(1.2-48) mg/dl and the median was 9.2 mg/dl,
ASDAS-CRP ranged between (1.04-4.8) with
median of 2.95, ASDAS-ESR ranged
between(1.03-5.23) with median of 2.84,
BASFI ranged between (0-9) and the median
was 4.5, Serum level Sema 3A ranged between
(0.22-31.48) ng/ml and the median was 2.93 .
Serum Sema 3A level showed a
statistically significant difference (p <0.05) in
AS patients’ group than in the control group,
with a median value of 2.93 and 1.83
respectively (Table 3).
Using ASDAS-CRP, 85% of AS
patients were active, while using ASDAS- ESR,
95% of patients were active (Table 4).
Table.5 shows statistically significant
difference of Serum Sema 3A level (ng/ml) in
ankylosing spondylitis patients regarding
ASDAS-CRP as the median value of serum
level of Sema 3A was 3.9 and 2 in active and
inactive AS patients. It also shows that serum
Sema 3A levels were significantly higher in AS
patients with peripheral arthritis than in AS
patients without peripheral arthritis with
statistically significant difference p<0.05 as
serum level of Sema 3A ranged between (2.13 31.48) in AS patients with peripheral arthritis
and between (0.22-2.64) in AS patients without
peripheral arthritis
Table.6 shows that a statistically
significant correlation between serum
level (ng/ml) and number of peripheral
449 | P a g e
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joints affected (r =0.58), ASDAS- CRP
(r=0.82), ASDAS-ESR (r=0.76) and BASFI.
Figure.1 shows that the optimum cut-off
for serum Sema 3A level to detect AS cases
from healthy one was (2.294 ng/ml) with 80%

sensitivity, 80% specificity and 80% accuracy.
It also shows that the optimum cut-off for
serum Sema 3A level to detect active and
inactive AS patients was (3.46 ng/ml) with 94%
sensitivity, 100% specificity and 95% accuracy.

Table (1): Demographic characteristics of both groups:
Ankylosing
Items
spondylitis
(n=20)
Age
Mean ±SD
Minimum- maximum
Sex
Males/females ratio
Disease Duration (years)
Mean ± SD
Minimum-maximum
χ 2 = Chi-square test.

Healthy control
(n=20)
Sig Test

p

t=0.04

0.97

32.8± 7.7
19-50
12/8(1.33)

32.7±7.8
18-50
12/8(1.33)

χ 2 =0

1

8.7±8.5
1-36

-

-

-

Table (2): Characteristics of patients with ankylosing spondylitis:
Median (minimum-maximum)
Lateral flexion (cm)
Schober test(cm)
Chest Expansion (Cm)
ESR (mm/h)

8.5(2-22)
12.75(11-16)
4.(2-6)
30(4-100)

CRP (mg/dl)
ASDAS CRP
ASDAS ESR

9.2(1.2-48)
2.95(1.04-4.8)
2.84(1.03-5.23)

Serum level Semaphorin 3A (ng/ml)

2.93(0.22-31.48)

BASFI
peripheral arthritis
present
absent
Uveitis
Yes
no

4.5(0-9)
No
14
6
1
19

%
70
30
5
95

ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, BASFI: Bath Ankylosing spondylitis
Functional Index, ASDAS-CRP: ankylosing spondylitis disease activity score using CRP, ASDAS
ESR: ankylosing spondylitis disease activity score using ESR.
Abd Elhady A., et al
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Table (3): Comparison between ankylosing spondylitis patients and healthy controls regarding
serum Semaphorin 3A level :
Ankylosing
Healthy control
MW
P
spondylitis
(n=20)
(n=20)
Serum level Semaphorin 3A
2.93(0.22-31.48)
1.83(0.04-3.91)
4.1
0.0005(*)
(ng/ml)
Median(minimum-maximum)
MW: Mann-Whitney test
* significance at p < 0.05.
Table (4): Disease activity in AS patients’ group:
No
ASDAS-CRP score
inactive (<1.3)
active (≥ 1.3)

ASDAS- ESR score
inactive (<1.3)
active (≥1.3)

%

3
17

15
85

1
19

5.0
95

ASDAS-CRP score: ankylosing spondylitis disease activity score using CRP, ASDAS -ESR:
ankylosing spondylitis disease activity score using ESR.
Table (5): Comparison serum Semaphorin 3A level of ankylosing spondylitis patients’ group
regarding ASDAS disease activity and peripheral arthritis:
Variables
Number of
Serum Semaphorin 3A
MW
p
AS patients
level (ng/ml):
Median(min-max)
ASDAS-CRP
Active (≥1.3)
17
3.9(2.17-31.48)
2.59
0.01(*)
Inactive (<1.3)
3
2 (0.22- 2.23)
Peripheral
arthritis
Present
absent

14
6

5.94 (2.13 -31.48)
2.4(0.22-2.64)
2.3

0.02(*)

MW: Mann-Whitney test. * significance at p < 0.05. ASDAS-CRP: ankylosing spondylitis disease
activity score using CRP
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Table (6): Correlation of serum Semaphorin 3A level with age, clinical parameters and disease
activity in ankylosing spondylitis patients:
Serum level Semaphorin 3A (ng/ml) in Ankylosing
spondylitis patients:
parameters
(r)

p

0.23

0.34

0.073

0.76

0.58*

0.007

0.01

0.97

0.107

0.65

-0.18

0.44

0.19

0.43

0.33

0.16

0.55*

0.01

0.82*

0.0001

0.76*

0.0001

0.69*
(r): correlation coefficient * Statistically significant p<0.05

0.001

Age
Disease duration per years
Number of peripheral joints affected
Occiput to wall (cm)
Lateral flexion (cm)
Schober test(cm)
Chest Expansion (Cm)
ESR
CRP
ASDAS CRP
ASDAS ESR
BASFI

(A)

(B)

*ROC: Receiver operating characteristic curve.
Figure (1). In figure A: ROC curve detects optimal cut off of serum Semaphorin level 3A between
ankylosing spondylitis patients and controls. In figure B: ROC curve detects optimal cut off of serum
Semaphorin 3A level between active and inactive AS patients according to ASDAS-CRP score.

Abd Elhady A., et al
https://digitalcommons.aaru.edu.jo/zumj/vol27/iss3/5

452 | P a g e
6

Abd Elhady et al.: CORRELATION OF SERUM SEMAPHORIN 3A WITH DISEASE ACTIVITY IN ANKYL

May. 2021 Volume 27 Issue 3

DISCUSSION
Ankylosing spondylitis (AS) is a chronic
disease that mostly affects patients aged 20- 30
years old. AS affects skeletal sites include the
spine, the sacroiliac joints and the entheses. AS
also affects extra-skeletal sites including the
eye, the heart and the gastro-intestinal tract (15).
In the present study, serum levels of
Semaphorin 3A (Sema 3A) were significantly
higher in AS patients than in normal subjects.
In addition, serum Sema 3A levels were higher
in active AS patients than in inactive patients.
In addition, serum level of Sema 3A was
compared between active and inactive AS
patients and it was observed that serum Sema
3A levels were significantly higher in active AS
patients than in inactive patients with the range
of serum Sema 3A levels was (2.2-31.477) in
the active AS patients versus (0.22- 2.32)in the
inactive patients (P<0.001).
This is consistent with the results of Liao
et al.,(16) and Qian et al., (3) who compared
between Sema 3A serum levels in AS patients
and Sema 3A serum levels in healthy controls
and found there was a significant difference of
between Sema 3A serum level in both groups
with higher levels in AS group.
However, these results are inconsistent
with the findings of Perrotta et al., (17) that there
was no difference between AS patients and
healthy controls as regarding serum Sema 3A .
This conflict may be explained by exclusion of
subjects with condition affecting serum level of
Sema 3A as taking anticoagulants, having
osteoporosis or renal failure or bony fracture in
this study and in the study of Liao et al., (1)
This study showed that serum level of Sema
3A significantly correlated with BASFI and AS
Disease Activity measured by ASDAS-CRP
and ASDAS-ESR.
There is a conflict between our results and
results of Liao et al.,(1) who found nonsignificant correlation between serum levels of
Sema 3A, BASFI and AS disease activity and
Perrotta et al., (17) who didn’t find any
correlation between serum levels of Sema 3A
with ASDAS-CRP. This may be due to small
sample size in our study.
Abd Elhady A., et al
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CONCLUSION
This study showed that Semaphorin 3A
serum levels were elevated in AS patients and
correlated with AS disease activity measured by
ASDAS-CRP, ASDAS-ESR, so, Sema 3A is a
potential a bio-marker for AS disease activity.
Semaphorin 3A serum levels were also
correlated with functional ability of AS patients
measured by BASFI.
We recommend further studies with
larger sample size for more evaluation of the
correlation of Semaphorin 3A with AS disease
activity as 19 out of 20 AS patients are active
according to ASDAS-ESR.
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